Its good to see that Zydus has started filing products in animal healthcare division for the US. Earlier, they had divested their Indian healthcare business to focus on regulated markets.
Disclosure: Not invested (no transactions in last-30 days)
2 Likes
- Plans for complex launches in US which will give meaningful traction in FY24.
- India formulations business is likely to stabilise as the company has optically initiated restructuring of business by rationalising slow moving SKUs.
- Huge Pipeline of Innovative Products like Saroglitazar Magnesium, Desidustat, anti-malarial compound, biologics and 505(b)(2) specialty initiatives
- EBITDA Margin guidance of 20% is maintained by management.
- Total 25-30 launches planned in US for FY23.
- Launch of Revlimid and clearance of Moraiya plant provide good growth prospects.
- Expected spend on R&D is 7-8% of revenues.
- Gross Margins in Consumer Wellness Business will get better in the coming quarters.
3 Likes
- EBITDA Margin guidance of 20% is maintained by management which is consistent with their guidance in Q2 FY23.
- They said in Q2FY23 that they are planning 25-30 launches in US in FY23 which they are consistent with. They filled 6 ANDA’s and 14 ANDA approvals they have got. Launched 6 new products as well. US Business is expected to grow in the next 2-3 years.
- Expected spend on R&D is 7-8% of revenues is what they said in Q2 FY23 which is consistent.
- Revlimid will still see high sales in Q4 as seen in Q2/Q3. There will be 4 transdermal launches in the next few years.
7 Likes
Zydus receives final approval for Tofacitininib 5 mg tablet and tentative approval for 10 mg.
It’s also eligible for 180 days of shared exclusivity for 5 mg strength.
Tofacitininib is a generic version of Pfizer”s XELJANZ which acts by inhibiting Janus kinases enzymes involved in the pathway of inflammatory process.
XELJANZ is indicated in patients with ankylosing spondylitis, moderate to severe rheumatoid arthritis, active psoriatic arthritis and moderate to severe active ulcerative colitis which are autoimmune inflammatory diseases.
Tofacitinib 5mg and 10 mg had annual sales of 900 mn in USA.(worldwide annual sales of 2.3 billion USD).
US FDA orange book shows few more approvals including Ajanta pharma and Micro Labs.
Ajanta pharma seems to have exclusivity for 10 mg tab as per below document of FDA.
Discl: invested
3 Likes
Zydus Lifesciences has received final approval from the USFDA to manufacture and market Estradiol Transdermal System USP, 0.014 mg/day.
Estradiol transdermal system is indicated for prevention of postmenopausal osteoporosis.
Ref: https://www.bseindia.com/xml-data/corpfiling/AttachLive/5e28376a-ff6b-4d81-b523-049d8f8c439a.pdf
Disc: Invested
3 Likes
- Guidance: R&D expenditure for FY24 is expected to be ~8% of revenue. EBITDA margin is expected to be at ~23% in FY24. The company would target to launch three new transdermal from the Moraiya site. Going ahead, it would continue to witness price erosions in the US market by low single digit. In India, it would continue to evaluate brand acquisition in order to fulfill the growth prospects. Revlimid volumes are expected to increase for the next 2 years. Africa and Europe business had a strong double-digit growth in Q1 due to good performance across the board in the branded business.
- US formulations business showed revenue growth and volume expansion. Received 28 new product approvals (incl. 5 tentative approvals) and launched 8 new products. 78 ANDAs pending approval with the USFDA. Single digit growth is expected in US for FY24.
- Indian formulations business saw 12% growth. Domestic market is expected to grow between 9-12% in FY24.
- Consumer Wellness business continued to maintain leadership position in key brands despite softer consumer demand. Urban demand was higher than rural demand. Recovery expected to increase now in rural areas.
1 Like
ZYDUS LIFESCIENCES -
Q2, FY 24 updates -
Sales - 4368 cr, up 9 pc
Gross Margins @ 66 pc
EBITDA - 1146 cr, up 41 pc ( margins @ 26 pc vs 21 pc YoY )
NP - 800 cr, up 53 pc
R&D expenses - 322 cr @ 7.2 pc of revenue (healthy rate)
Capex for the Qtr at 216 cr
3 US FDA inspections happened in Q2 @ oral solid facilities I and III at Ahmedabad SEZ, Biologics fill-finish facility at Zydus Biotech park - all received EIR
Geography wise sales breakup -
India branded formulations - 32 pc - grew by 5 pc YoY despite delayed monsoons and hence the delay in acute season . Maintained leadership in Nephrology space. Grew strongly in Oncology space. Company’s biggest segments - Cardio, Respiratory, Anti-Infectives. Company has 08 brands among top 300 brands in India
India consumer wellness - 10 pc - grew by 3 pc YoY. Own some category leading brands - Everyouth, SugarFree, Glucon D, Nycil. Also own - Complain ( no 3 in its category )
US business - 44 pc. Grew 9 pc YoY. Filed 4 new ANDAs. Launched Indomethacin suppository in Q2 - granted 180 days exclusivity
EM + EU - 10 pc. Grew 17 pc YoY in Q2
APIs - 3 pc
Alliances - 1 pc
Other comments -
Company has already launched 13 Biosimilars in India
Acquired UK based LiqMeds group - for a total consideration of 690 cr. LiqMeds specialises in Oral Liquid dosage forms mostly targeted at geriatric and pediatric patients
LiqMeds has 05 - 505 b(2) approved products in US to be commercialised in future. Also has 16 approved products in UK - yet to launch most of them
Zydus has a 505 b(2) approval for Sitaglaptin. The company has exclusivity for the foreseeable future. However, since it’s not a substitutable product, it will take time for the company to ramp it up. Since it is not a generic approval, don’t see any pricing pressure
Speciality products in US / Europe - company focussing on rare/orphan disease and other unmet needs. Company already has approval for 01 product - NULIBERY - an injectable used to prevent mortality in a rare paediatric disorder. Another asset/product is awaiting approval. Aim to acquire at least 2 more products ( late stage / awaiting commercialisation ) going forward. Aim to scale this speciality business to $ 100 million kind of annual sales run rate in medium term (next 3 yrs). Also have 02 more products under own development
Revlimid sales shall accrue to the company only in Q1, Q4 every year till FY 26. Gross margins in Q2 were strong despite NIL sales from Revlimid
Company is building in one competitor for this FY and one more competitor by next FY for its product - ASOCOL in US
Very likely to clock double digit growth in US business in this FY
Company has 6500 MRs in India. Likely to add more in next FY
Lower RM costs have helped company’s Gross Margins
Launching 02 transdermal products in US in this FY. Likely to add 02 more in the next FY. Also expected to launch 01 exclusive product/yr for FY 25,26,27 subject to approvals, litigations etc
Disc: hold a small tracking position. Will add only if there are triggers like successful speciality / exclusive launches. Biased. Not SEBI registered
3 Likes
Zydus Lifesciences ( Very Bullish commentary and important business developments ) -
Q3 results and concall highlights -
Sales - 4505 vs 4257 cr
Gross margins @ 67 vs 64 pc
EBITDA - 1102 vs 956 cr ( margins @ 24.5 vs 22.5 pc )
R&D expenses at 314 vs 344 cr ( @ 7 pc vs 8 pc of sales )
PAT - 789 vs 622 cr
Q3 Capex @ 213 cr. 9M FY 24 capex @ 650 cr
Region wise performance -
India -
Sales @ 1427 vs 1231 cr, up 16 pc
Branded India business and new Innovative portfolio grew strongly. Witnessed strong growth in Cardiac, Anti-Infective and Anti-Diabetic portfolio
Continue to maintain leadership in Nephrology
Company has 8 brands in top 300 brands in India. Also has a commercial portfolio of 13 Biosimilars in India. Has 09 more biosimilar molecules in pipeline
Company has also commercialised 03 NCEs in India - Saroglitazar ( for NAFLD ), Twinrab ( a biologic drug used for treatment in Rabies ) and Desidustat ( for Anemia )
India - FMCG segment -
Sales @ 397 vs 412 cr
FMCG segment witnessed weak demand scenario
Everyouth, Nycil - witnessed strong growth
Sugarfree, Nycil, Glucon D, Everyouth (peel-off) maintained their market leadership positions
US formulations -
Sales @ 1842 vs 1925 cr
Base business saw strong volume growth. Launched 11 new products including - ZITUVIA ( a 505(b)(2) product )
Emerging Markets -
Sales @ 493 vs 378 cr
Witnessed strong growth in Asia Pacific, Africa and Europe
Innovation -
Commenced phase II trials for ZYIL 1 for Parkinson’s. Phase II trials are also on for this molecule in India for ALS ( a rare neurodegenerative disease )
Completed phase II trials in India for ZY9489, an anti-malarial drug
NCE - Saroglitazar Magnesium ( already approved in India for non-alcoholic fatty lever disease ) - commenced recruitment of patients for Phase II trials in US
Completed asset transfer of CUTX - 101, a Copper Histidinate product for treatment of Menkes Disease. Rolling out NDA application for the same in US
Company is presently in the process of adding 700 MRs in India to accelerate the formulations business. Full effects should be visible by Q1 FY 25
Acquisition of LiqMeds ( a UK based company ) specialising in Oral Liquid formulations - Zydus Life acquired LiqMeds in Oct 23 for 700 cr plus yearly payouts till FY 26 on achievement of certain performance liked milestones. It’s already a profitable business. Most of their products are based on 505(b)(2) opportunities. The business is expected to scale up over next 1-2 yrs
All three NCEs launched in India are doing really well. Company expects, Saroglitazar to become its biggest brand in times to come !!!
Company expects a slow pickup for ZITUVIA in US. It’s an important launch for the company. Should add significant value in FY 25
Company continues to enjoy exclusivity for Asacol ( used to treat inflammatory bowel diseases ) in US mkts
Company reported strong numbers and healthy margins even without Revlimid sales in Q3. Revlimid sales are expected to be recorded in Q4 and Q1 FY 25
Have a good pipeline of exiting launches in US till FY 27
EM business momentum is likely to sustain going fwd. Likely to keep growing in double digits
Company has launched a bunch of transdermal products in US in FY 24. Over next 2-3 yrs, these can generate 400 - 500 cr topline for the company
Disc: holding, inclined to add more, biased